Please assess the completion status of the following clinical trial:

Trial Title: Third Optimizing Anti-Platelet Therapy in Diabetes MellitUS (OPTIMUS-3)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 Diabetes Mellitus and on oral or parenteral hypoglycemic therapy for at least 1 month.~* History of Coronary Artery Disease with or without other types of vascular disease (such as peripheral vascular disease).~* Taking Aspirin 75-325 mg/day for at least 1 week prior to randomization.~* Between the ages of 18-74 years old.~* If a woman of child bearing age, must not be pregnant and must agree to use reliable method of birth control during the duration of the study.~Exclusion Criteria:~* Thienopyridine therapy within 30 days or have a defined need for thienopyridine treatment.~* Coronary Artery Bypass Graft (CABG) or Percutaneous Coronary Intervention (PCI) with no stent placed within 30 days.~* Planned coronary revascularization~* Hemoglobin A1c (HbA1c) \> or equal to 10 mg/dL within the last 3 months.~* Received fibrolytic therapy \<24 hours prior to randomization.~* Received non-fibrin-specific fibrinolytic therapy \<48 hours prior to randomization.~* At risk of bleeding.~* History of ischemic stroke, transient ischemic attack (TIA), intercranial neoplasm, arteriovenous malformation, or aneurysm.~* Body weight \<60 kilograms (kg).~* International Normalized Ratio (INR) \>1.5, platelet count \<100,000/mm3, or anemia (hemoglobin \<10 gm/dL) within 1 week of study entry.~* Are receiving or will receive oral anticoagulation or antiplatelet treatment therapy.~* Are being treated with daily non-steroidal anti-inflammatory drugs (NSAIDS).~* Are pregnant, breast-feeding or plan to become pregnant.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- Prasugrel (Type: EXPERIMENTAL): Oral prasugrel 60-mg loading dose, followed by 6 to 9 days of prasugrel 10-mg/day tablet maintenance dose.
- Clopidogrel (Type: ACTIVE_COMPARATOR): Oral clopidogrel 600-mg loading dose, followed by 6 to 9 days of clopidogrel 150-mg/day tablet maintenance dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).